Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
about
Contribution of CXCL12 secretion to invasion of breast cancer cells.Parallel visualization of multiple protein complexes in individual cells in tumor tissueErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2.Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinasesThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationTyrosine kinase signalling in breast cancerFunctional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItInsulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant diseaseOrchestration of ErbB3 signaling through heterointeractions and homointeractions.Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondPhosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cellsWhole-genome association study of bipolar disorderDifferential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytesDDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cellsHeterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanismsSpecific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorDevelopment of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensorIgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachControlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimersThe ErbB signaling network: receptor heterodimerization in development and cancerc-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptorSystem theoretical investigation of human epidermal growth factor receptor-mediated signalling.Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Structure-function analysis of nucleolin and ErbB receptors interactions.Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancerPertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.Design and applications of bispecific heterodimers: molecular imaging and beyondPicking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian CancerErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation.Role of receptor tyrosine kinases and their ligands in glioblastoma.Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.Bivalence of EGF-like ligands drives the ErbB signaling networkDifferential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
P2860
Q22000754-D74A8578-4A7D-4547-982D-F973DEB92A24Q24320208-7A2B4ADF-8688-4B3C-A154-F3C1C401C336Q24522643-A91024F5-774B-4A58-BA07-BC9BB6D06E97Q24536142-CBA0A026-554C-4652-A783-14A8ECB80430Q24538330-7D9B6FAB-5C65-4C42-AE09-7602B141C5CFQ24651825-7A4247C7-F22C-4C8A-ADB4-56A8C41923ABQ24678674-1957AEB4-FA69-453D-A404-5E5A286E8BBDQ24802908-06E0635F-23C7-4511-AAAD-992B4824EE87Q24813543-C7471819-9CF4-415F-9660-F60BE3F10C1EQ26752780-42890BD4-F079-4FC1-8166-25A246DABA4CQ26800001-F210A032-ABD7-42EF-9678-80CEAF5B70CDQ27306737-6E01C675-2A29-425F-9370-2FF51A80A1A2Q27691330-CB0349A6-2F33-4813-9632-CAAD07C939EAQ28080730-232E144E-AA90-4340-9E24-EDB3E36DC390Q28269146-9FE1A475-B733-4790-9396-21EA98A89980Q28271419-72F1C080-EB35-480B-9CB1-8E39DE4CEE17Q28360375-13D2A3BD-D939-4267-876E-83880EB18082Q28363500-5F9763A1-51F9-4B02-AB05-2BCC33C62866Q28364239-39C44918-5A51-49B3-BDDC-5588A98955D2Q28368986-E0FC9839-9B93-42D1-8CC7-E71802609AE1Q28541161-BEF0D7BA-4E7D-4B05-94DD-F3CC6D9B6BE5Q28655505-64DF9799-95BF-4C9F-B6A5-19B638DD512AQ28679173-7E19F077-7752-4420-B6B5-BB073B08A213Q29617919-DC900F49-8CB1-4F32-8951-1E348F95EE48Q29618661-DAEC7C9D-DA1A-4A21-82CD-B856BFF609CAQ33388432-EB8917F3-5F6A-48DC-8AFD-9AD594638989Q33412770-5EBADD40-C3A0-40FF-B7B4-3D1F10DDE599Q33478425-38ECB4CD-4BB0-4D28-9A78-858F18C5542BQ33533628-FD408BFD-B3D7-4FC5-9E97-DB9D45B63C4EQ33680109-5A043A91-6907-490E-B2DF-F46AE3D66A07Q33692428-9DE5C024-E0B1-4EE7-9BA2-153D524613B0Q33732587-710F04E3-0F3D-4E71-8D27-709D584E5E7CQ33756409-32690A66-E14C-4A7E-81A2-F0A0BA4F7AB1Q33781099-25C77780-7C9F-48C5-8AF4-F91DBFD502F2Q33781714-A8044A6B-3EA8-4334-A0CB-D8F4EB2786DAQ33883849-EE407EC0-7B67-4194-926D-DF4CD54BB36AQ33884776-CCBB73A1-82CD-4405-8FD6-1499F98BF7B3Q33887274-3555E5D8-033A-4A74-8433-19AFFCBE3267Q33888963-AD43430D-3FBE-44C8-8BE4-42CA15278BF5Q33890758-AAED7AAB-2CA3-429B-8024-C6AF670C742C
P2860
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
description
1996 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1996
@ast
im Mai 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1996/05/15)
@sk
vědecký článek publikovaný v roce 1996
@cs
wetenschappelijk artikel (gepubliceerd op 1996/05/15)
@nl
наукова стаття, опублікована в травні 1996
@uk
مقالة علمية (نشرت في 15-5-1996)
@ar
name
Diversification of Neu differe ...... natorial receptor interactions
@ast
Diversification of Neu differe ...... natorial receptor interactions
@en
Diversification of Neu differe ...... natorial receptor interactions
@nl
type
label
Diversification of Neu differe ...... natorial receptor interactions
@ast
Diversification of Neu differe ...... natorial receptor interactions
@en
Diversification of Neu differe ...... natorial receptor interactions
@nl
prefLabel
Diversification of Neu differe ...... natorial receptor interactions
@ast
Diversification of Neu differe ...... natorial receptor interactions
@en
Diversification of Neu differe ...... natorial receptor interactions
@nl
P2093
P2860
P3181
P1433
P1476
Diversification of Neu differe ...... natorial receptor interactions
@en
P2093
B. J. Ratzkin
G. Levkowitz
H. Waterman
L. Klapper
L. Soussan
R. Pinkas-Kramarski
P2860
P304
P3181
P407
P577
1996-05-15T00:00:00Z